ADAPROLOL MALEATE

Details

Stereochemistry	RACEMIC
Molecular Formula	C26H39NO4.C4H4O4
Molecular Weight	545.6643
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)\C=C/C(O)=O.CC(C)NCC(O)COC1=CC=C(CC(=O)OCCC23CC4CC(CC(C4)C2)C3)C=C1

InChI

InChIKey=WEBILLRFBZTUIX-BTJKTKAUSA-N

InChI=1S/C26H39NO4.C4H4O4/c1-18(2)27-16-23(28)17-31-24-5-3-19(4-6-24)12-25(29)30-8-7-26-13-20-9-21(14-26)11-22(10-20)15-26;5-3(6)1-2-4(7)8/h3-6,18,20-23,27-28H,7-17H2,1-2H3;1-2H,(H,5,6)(H,7,8)/b;2-1-

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16594634
Curator's Comment: description was created based on several sources, including: https://www.ncbi.nlm.nih.gov/pubmed/8773927 | https://www.ncbi.nlm.nih.gov/pubmed/10608921

Adaprolol is a beta-adrenergic antagonist that is being developed as a topical agent to treat glaucoma. Adaprolol demonstrated a safer cardiovascular profile, especially in the population over 70 years old. It was in Phase II clinical trials for the treatment of glaucoma. This research has been discontinued.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Adrenergic receptor beta 89 Target ID: CHEMBL2094118 Sources: http://adisinsight.springer.com/drugs/800003472 \| https://www.ncbi.nlm.nih.gov/pubmed/8773927	Antagonist 2849

Conditions

Condition	Modality	Targets	Highest Phase	Product
Glaucoma 57 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8773927	Primary		Phase II 1147	Unknown Approved Use Unknown
Tachyarrhythmia 17 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1673212	Primary		Preclinical	Unknown Approved Use Unknown

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY34049	https://www.001chemical.com/chem/101479-70-3
ABI Chem	AC1L1TTB
ABI Chem	AC1Q66Q3
Molcore	MC34049	https://www.molcore.com/product/101479-70-3
Smolecule	S517206	http://www.smolecule.com/products/s517206
THE BioTek	bt-257812	https://www.thebiotek.com/product/inhibitors/bt-257812

PubMed

Title	Date	PubMed
Ophthalmic drug design based on the metabolic activity of the eye: soft drugs and chemical delivery systems.	2005-12-07	16594634
Soft drug design: general principles and recent applications.	2000-01	10608921
Synthesis and pharmacological activity of adaprolol enantiomers: a new soft drug for treating glaucoma.	1996	8773927
Cardiac electrophysiologic effects of adaprolol maleate, a new beta-blocker, in closed chest dogs.	1991	1673212

Sample Use Guides

In Vivo Use Guide

Rabbit: 0.1 mL of 0.25% solution into each eye

Route of Administration: Topical

In Vitro Use Guide

Unknown

Name

Type

Language

ADAPROLOL MALEATE

Official Name

English

CDDD 2803

Preferred Name

English

BENZENEACETIC ACID, 4-(2-HYDROXY-3-((1-METHYLETHYL)AMINO)PROPOXY)-, 2-TRICYCLO(3.3.1.1(SUP 3,7))DEC-1-YLETHYL ESTER, (±)-, (Z)-2-BUTENEDIOATE (1:1) (SALT)

Systematic Name

English

CDDD-2803

Code

English

ADAPROLOL MALEATE [USAN]

Common Name

English

(±)-2-(1-ADAMANTYL)ETHYL (P-(2-HYDROXY-3-(ISOPROPYLAMINO)PROPOXY)PHENYL)ACETATE, MALEATE (1:1) (SALT)

Systematic Name

English

HGP-2

Code

English

HGP 2

Code

English

Classification Tree Code System Code

NCI_THESAURUS

C29576